TEM secures FDA clearance for its AI-powered ECG tool targeting heart failure, as AI ECG adoption accelerates.

Approval of Kerendia was based on results from the Phase III FINEARTS-HF trial, which demonstrated statistically significant ...

BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that Henry Ford Health in Detroit, ...

Background Although treatment options for heart failure (HF) have improved, advanced HF (AdHF) remains a challenging ...

Germany’s Bayer has announced that the US Food and Drug Administration (FDA) has approved Kerendia (finerenone) to treat ...

US FDA approves Bayer’s finerenone for new indication in patients with heart failure with left ventricular ejection fraction of ≥ 40%: Berlin Wednesday, July 16, 2025, 13:00 H ...

According to a report from Research And Markets, the AI in Ophthalmology Market was valued at USD 209.23 million in 2024, and is projected ...

A 74-year-old woman develops haemolytic anaemia and stress cardiomyopathy after a tick bite, highlighting a rare cardiac ...

Berlin: Bayer has received approval from the U.S. Food and Drug Administration (FDA) for finerenone (Kerendia), a ...

Cambridge, Mass.-based Royal Philips (NYSE: PHG), a global leader in health technology, today announced the launch of the Philips ECG AI Marketplace, a platform that gives cardiac care teams access to ...

Discover a study introducing MAARS, a multimodal AI model that accurately predicts sudden cardiac death risk in HCM patients.

The AI model effectively spotted all subtypes of amyloidosis in the dataset, with an area under the receiver-operating characteristic curve (AUROC) of 0.93, a sensitivity of 85% for identifying ...